Skinvisible Financials
This page shows Skinvisible (SKVI) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 16 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Tiny revenue and near-zero cost of sales leave this business defined by liability-supported overhead, not by product economics.
Between FY2024 and FY2025, free cash burn narrowed from-$79.1K to-$42.5K even though revenue stayed stuck at$20K , which means the smaller cash drain came from expense restraint and lighter capex rather than a healthier sales engine. At the same time, liabilities increased by about$1.0M while cash fell to$2.6K , so the balance sheet became more obligation-heavy even as operating burn eased.
The reported gross margin is essentially
Liquidity is extremely thin: FY2025 current assets were just
Financial Health Signals
Based on FY2025 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →
Health score ≠ stock price. This rates the quality of Skinvisible's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Skinvisible has an operating margin of -2481.6%, meaning the company retains $-2482 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses. This is up from -2948.0% the prior year.
Skinvisible's revenue grew a modest 0.0% year-over-year to $20K. This slow but positive growth earns a score of 33/100.
Skinvisible's current ratio of 0.01 is below the typical benchmark, resulting in a score of 0/100. This tight liquidity could limit financial flexibility if cash inflows slow.
While Skinvisible generated -$38K in operating cash flow, capex of $4K consumed most of it, leaving -$42K in free cash flow. This results in a low score of 0/100, reflecting heavy capital investment rather than weak cash generation.
Skinvisible passes 1 of 9 financial strength tests. No profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), 1 of 2 efficiency signals pass.
Skinvisible earns $-0.9 in operating income for every $1 of interest expense (-$496K vs $572K). This narrow margin raises concern about the company's ability to service its debt if operating income declines.
Key Financial Metrics
Earnings & Revenue
Skinvisible generated $20K in revenue in fiscal year 2025. This represents an increase of 0.0% from the prior year.
Skinvisible's EBITDA was -$476K in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 16.4% from the prior year.
Cash & Balance Sheet
Skinvisible generated -$42K in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 46.2% from the prior year.
Skinvisible held $3K in cash against $0 in long-term debt as of fiscal year 2025.
Skinvisible had 5M shares outstanding in fiscal year 2025. This represents an increase of 1.6% from the prior year.
Margins & Returns
Skinvisible's gross margin was 100.0% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is up 0.0 percentage points from the prior year.
Skinvisible's operating margin was -2481.6% in fiscal year 2025, reflecting core business profitability. This is up 466.4 percentage points from the prior year.
Capital Allocation
Skinvisible invested $4K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 55.7% from the prior year.
SKVI Income Statement
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $5K0.0% | $5K0.0% | $5K0.0% | $5K0.0% | $5K0.0% | $5K0.0% | $5K0.0% | $5K |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | $5K0.0% | $5K0.0% | $5K0.0% | $5K0.0% | $5K0.0% | $5K0.0% | $5K0.0% | $5K |
| R&D Expenses | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| SG&A Expenses | $126K+10.4% | $114K+7.7% | $106K-22.2% | $136K-2.7% | $140K-29.6% | $199K+60.2% | $124K-13.2% | $143K |
| Operating Income | -$126K-10.3% | -$114K-7.6% | -$106K+22.2% | -$136K+2.6% | -$140K+29.6% | -$199K-59.0% | -$125K+12.4% | -$143K |
| Interest Expense | $141K-2.0% | $144K0.0% | $144K+1.0% | $143K+1.1% | $141K-16.3% | $169K+0.5% | $168K+0.7% | $167K |
| Income Tax | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | -$267K | N/A | -$250K+8.8% | -$274K+2.3% | -$281K-189.3% | $315K+209.8% | -$287K+5.6% | -$303K |
| EPS (Diluted) | N/A | N/A | N/A | N/A | N/A | N/A | $-0.06+14.3% | $-0.07 |
SKVI Balance Sheet
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $119K-6.4% | $128K-4.5% | $134K-6.8% | $143K-4.1% | $150K-5.5% | $158K+6.4% | $149K-8.8% | $163K |
| Current Assets | $24K-11.4% | $28K-3.3% | $28K-14.0% | $33K-13.6% | $38K-8.9% | $42K+53.4% | $27K-23.6% | $36K |
| Cash & Equivalents | $2K-31.4% | $3K+306.2% | $645+437.5% | $120-99.1% | $13K+29.6% | $10K+1588.9% | $612-91.2% | $7K |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | $5K0.0% | $5K0.0% | $5K0.0% | $5K+963.8% | $470-90.6% | $5K+400.0% | $1K-80.0% | $5K |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $10.6M+2.5% | $10.4M+2.5% | $10.1M+2.4% | $9.9M+2.8% | $9.6M+2.6% | $9.4M-6.3% | $10.0M+2.8% | $9.7M |
| Current Liabilities | $5.3M+5.2% | $5.0M+5.3% | $4.8M+5.3% | $4.5M+6.3% | $4.3M+16.4% | $3.7M-21.2% | $4.6M+15.4% | $4.0M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | -$10.5M-2.6% | -$10.3M-2.6% | -$10.0M-2.6% | -$9.8M-2.9% | -$9.5M-2.8% | -$9.2M+6.5% | -$9.9M-3.0% | -$9.6M |
| Retained Earnings | -$41.3M-0.7% | -$41.0M-0.6% | -$40.8M-0.6% | -$40.5M-0.7% | -$40.2M-0.7% | -$39.9M+0.8% | -$40.3M-0.7% | -$40.0M |
SKVI Cash Flow Statement
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$822-141.6% | $2K+276.9% | $524+105.7% | -$9K+71.0% | -$32K-87.6% | -$17K-34.8% | -$13K+55.3% | -$28K |
| Capital Expenditures | N/A | $0+100.0% | -$1 | N/A | N/A | $0 | $0 | N/A |
| Free Cash Flow | N/A | $2K+277.6% | $523 | N/A | N/A | -$17K-34.8% | -$13K | N/A |
| Investing Cash Flow | N/A | $0-100.0% | $1 | N/A | N/A | $0 | $0 | N/A |
| Financing Cash Flow | N/A | $0 | $0 | $0-100.0% | $35K+30.6% | $27K+332.1% | $6K-83.0% | $36K |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
SKVI Financial Ratios
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 100.0%0.0pp | 100.0%0.0pp | 100.0%0.0pp | 100.0%0.0pp | 100.0%0.0pp | 100.0%0.0pp | 100.0%0.0pp | 100.0% |
| Operating Margin | -2518.8%-235.4pp | -2283.4%-162.2pp | -2121.1%+603.6pp | -2724.7%+72.3pp | -2797.0%+1177.8pp | -3974.9%-1475.5pp | -2499.4%+354.5pp | -2853.9% |
| Net Margin | -5343.7% | N/A | -5004.9%+483.6pp | -5488.5%+131.6pp | -5620.1%-11915.5pp | 6295.4%+12027.5pp | -5732.1%+336.9pp | -6069.0% |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | -223.7% | N/A | -187.3%+4.1pp | -191.4%-3.5pp | -187.9%-386.9pp | 199.0%+391.8pp | -192.8%-6.7pp | -186.1% |
| Current Ratio | 0.000.0 | 0.010.0 | 0.010.0 | 0.010.0 | 0.010.0 | 0.010.0 | 0.010.0 | 0.01 |
| Debt-to-Equity | -1.010.0 | -1.010.0 | -1.010.0 | -1.010.0 | -1.020.0 | -1.020.0 | -1.020.0 | -1.02 |
| FCF Margin | N/A | 39.5%+29.0pp | 10.5% | N/A | N/A | -338.2%-87.4pp | -250.8% | N/A |
Note: Shareholder equity is negative (-$10.3M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.01), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Frequently Asked Questions
What is Skinvisible's annual revenue?
Skinvisible (SKVI) reported $20K in total revenue for fiscal year 2025. This represents a 0.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Skinvisible's revenue growing?
Skinvisible (SKVI) revenue grew by 0% year-over-year, from $20K to $20K in fiscal year 2025.
What is Skinvisible's EBITDA?
Skinvisible (SKVI) had EBITDA of -$476K in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Skinvisible's gross margin?
Skinvisible (SKVI) had a gross margin of 100.0% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Skinvisible's operating margin?
Skinvisible (SKVI) had an operating margin of -2481.6% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Skinvisible's free cash flow?
Skinvisible (SKVI) generated -$42K in free cash flow during fiscal year 2025. This represents a 46.2% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Skinvisible's operating cash flow?
Skinvisible (SKVI) generated -$38K in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Skinvisible's total assets?
Skinvisible (SKVI) had $128K in total assets as of fiscal year 2025, including both current and long-term assets.
What are Skinvisible's capital expenditures?
Skinvisible (SKVI) invested $4K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
What is Skinvisible's current ratio?
Skinvisible (SKVI) had a current ratio of 0.01 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.
What is Skinvisible's debt-to-equity ratio?
Skinvisible (SKVI) had a debt-to-equity ratio of -1.01 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Skinvisible's cash runway?
Based on fiscal year 2025 data, Skinvisible (SKVI) had $3K in cash against an annual operating cash burn of $38K. This gives an estimated cash runway of approximately 1 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
Why is Skinvisible's debt-to-equity ratio negative or unusual?
Skinvisible (SKVI) has negative shareholder equity of -$10.3M as of fiscal year 2025, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
What is Skinvisible's Piotroski F-Score?
Skinvisible (SKVI) has a Piotroski F-Score of 1 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Can Skinvisible cover its interest payments?
Skinvisible (SKVI) has an interest coverage ratio of -0.9x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Skinvisible?
Skinvisible (SKVI) scores 6 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.